Nicholas George Nickols

Title(s)Department Vice Chair, Radiation Oncology
SchoolMedicine
vCardDownload vCard
    Other Positions
    Title(s)Associate Professor-in-residence, Radiation Oncology

    Title(s)Associate Professor-in-residence, Urology


    Collapse Research 
    Collapse Research Activities and Funding
    Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
    NIH I01CX001575Jul 1, 2018 - Jun 30, 2023
    Role: Principal Investigator
    Programmable DNA-binders as radio-modulators and therapeutics for prostate cancer
    NIH IK2BX002520Oct 1, 2014 - Sep 30, 2017
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Treatment Response Assessment According to Updated PROMISE Criteria in Patients with Metastatic Prostate Cancer Using an Automated Imaging Platform for Identification, Measurement, and Temporal Tracking of Disease. Eur Urol Oncol. 2024 Nov 08. Benitez CM, Sahlstedt H, Sonni I, Brynolfsson J, Berenji GR, Juarez JE, Kane N, Tsai S, Rettig M, Nickols NG, Duriseti S. PMID: 39521638.
      View in: PubMed   Mentions:
    2. Corrigendum to "Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774)" [Eur Urol. 86(1) (2024) 52-60]. Eur Urol. 2024 Nov 08. Armstrong WR, Kishan AU, Booker KM, Grogan TR, Elashoff D, Lam EC, Clark KJ, Steinberg ML, Fendler WP, Hope TA, Nickols NG, Czernin J, Calais J. PMID: 39521695.
      View in: PubMed   Mentions:
    3. Oncogenic Alterations, Race, and Survival in US Veterans with Metastatic Prostate Cancer Undergoing Somatic Tumor Next Generation Sequencing. bioRxiv. 2024 Oct 25. Valle LF, Li J, Desai H, Hausler R, Haroldsen C, Chatwal M, Ojo M, Kelley MJ, Rebbeck T, Rose BS, Rettig MB, Nickols NG, Garraway IP, Yamoah K, Maxwell KN. PMID: 39484518; PMCID: PMC11527339.
      View in: PubMed   Mentions:
    4. Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): A Pooled Analysis of Five Randomized Trials from the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium. Eur Urol. 2024 Sep 19. Ong WL, Romero T, Roy S, Nikitas J, Joseph D, Zapatero A, Malone S, Morgan SC, Steinberg ML, Valle LF, Zaorsky NG, Martin Ma T, Rettig MB, Nickols N, Jiang T, Reiter RE, Eleswarapu SV, Maldonado X, Sun Y, Nguyen PL, Millar JL, Martin JM, Spratt DE, Kishan AU, MARCAP Consortium Investigators. PMID: 39304428.
      View in: PubMed   Mentions:    Fields:    
    5. Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naïve Prostate Cancer. Eur Urol. 2024 Sep 17. Weiner AB, Agrawal R, Wang NK, Sonni I, Li EV, Arbet J, Zhang JJH, Proudfoot JA, Hong BH, Davicioni E, Kane N, Valle LF, Kishan AU, Pra AD, Ghadjar P, Sweeney CJ, Nickols NG, Karnes RJ, Shen J, Rettig MB, Czernin J, Ross AE, Lee Kiang Chua M, Schaeffer EM, Calais J, Boutros PC, Reiter RE. PMID: 39294048.
      View in: PubMed   Mentions:    Fields:    
    6. Systematic review and recommendations for re-irradiation for intraprostatic radiorecurrent prostate cancer after definitive radiation therapy. World J Urol. 2024 Sep 12; 42(1):520. Saripalli AL, Venkatesulu BP, Nickols NG, Valle LF, Harkenrider MM, Kishan AU, Solanki AA. PMID: 39264453.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. Prostate-Specific Membrane Antigen PET/CT-Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2024 Sep 03; 65(9):1387-1394. Nikitas J, Castellanos Rieger A, Farolfi A, Seyedroudbari A, Kishan AU, Nickols NG, Steinberg ML, Valle LF, Rettig M, Czernin J, Calais J. PMID: 39089811.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Challenges and Opportunities in Developing an Oncology Clinical Trial Network in the United States Veterans Affairs Health Care System: The VA STARPORT Experience. Curr Oncol. 2024 Aug 21; 31(8):4781-4794. Solanki AA, Zheng K, Skipworth AN, Robin LM, Leparski RF, Henry E, Rettig M, Salama JK, Ritter T, Jones J, Quek M, Chang M, Block AM, Welsh JS, Kumar A, Chao HH, Chen AC, Shapiro R, Bitting RL, Kwon R, Stross W, Puckett L, Wong YN, Nickols NG, Carlson K, VA STARPORT Investigators Group. PMID: 39195341; PMCID: PMC11353739.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. Transcriptomic Profiling of Primary Prostate Cancers and Nonlocalized Disease on Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: A Multicenter Retrospective Study. JCO Precis Oncol. 2024 Jul; 8:e2400161. Nikitas J, Subramanian K, Gozal NB, Ricaurte-Fajardo A, Li E, Proudfoot JA, Davicioni E, Marciscano AE, Osborne JR, Barbieri CE, Armstrong WR, Smith CP, Valle LF, Steinberg ML, Boutros PC, Nickols NG, Rettig MB, Reiter R, Weiner AB, Calais J, Czernin J, Ross AE, Kim EH, Nagar H, Kishan AU. PMID: 39013135.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    10. Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial). J Nucl Med. 2024 Jul 01; 65(7):1076-1079. Nikitas J, Lam E, Booker KA, Fendler WP, Eiber M, Hadaschik B, Herrmann K, Hirmas N, Lanzafame H, Stuschke M, Czernin J, Steinberg ML, Nickols NG, Kishan AU, Calais J. PMID: 38664019; PMCID: PMC11218723.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    11. Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial. Eur Urol. 2024 Jun; 85(6):517-520. Nikitas J, Rettig M, Shen J, Reiter R, Lee A, Steinberg ML, Valle LF, Sachdeva A, Romero T, Calais J, Czernin J, Nickols NG, Kishan AU. PMID: 38494380; PMCID: PMC11386258.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    12. Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer. Eur Urol. 2024 Aug; 86(2):190-193. Nickols NG, Tsai S, Kane N, Tran S, Ghayouri L, Diaz-Perez S, Thein M, Anderson-Berman N, Eason J, Kishan AU, Steinberg ML, Reiter RE, Lee SP, Gin GE, Kwon R, Chang MG, Chao HH, Solanki AA, Sexton R, Lewis M, Lorentz W, Cheung MK, Gage DL, Duriseti S, Valle L, Berenji G, Aronson WJ, Garraway IP, Rettig MB. PMID: 38490853.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    13. Neighborhood Deprivation, Race and Ethnicity, and Prostate Cancer Outcomes Across California Health Care Systems. JAMA Netw Open. 2024 Mar 04; 7(3):e242852. Wadhwa A, Roscoe C, Duran EA, Kwan L, Haroldsen CL, Shelton JB, Cullen J, Knudsen BS, Rettig MB, Pyarajan S, Nickols NG, Maxwell KN, Yamoah K, Rose BS, Rebbeck TR, Iyer HS, Garraway IP. PMID: 38502125; PMCID: PMC10951732.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    14. Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774). Eur Urol. 2024 Jul; 86(1):52-60. Armstrong WR, Kishan AU, Booker KM, Grogan TR, Elashoff D, Lam EC, Clark KJ, Steinberg ML, Fendler WP, Hope TA, Nickols NG, Czernin J, Calais J. PMID: 38290964.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    15. Quantifying Intrafraction Motion and the Impact of Gating for Magnetic Resonance Imaging-Guided Stereotactic Radiation therapy for Prostate Cancer: Analysis of the Magnetic Resonance Imaging Arm From the MIRAGE Phase 3 Randomized Trial. Int J Radiat Oncol Biol Phys. 2024 Apr 01; 118(5):1181-1191. Neylon J, Ma TM, Savjani R, Low DA, Steinberg ML, Lamb JM, Nickols NG, Kishan AU, Cao M. PMID: 38160916.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    16. Prostate-Specific Antigen Response to Androgen Deprivation Therapy in the Neoadjuvant Setting for High-Risk Prostate Adenocarcinoma (PIRANHA): Pooled Analysis of Two Randomized Clinical Trials. Int J Radiat Oncol Biol Phys. 2024 Jul 01; 119(3):826-831. Nikitas J, Ong WL, Carrier N, Romero T, Millar J, Steinberg ML, Rettig MB, Boutros PC, Reiter R, Nickols NG, Valle L, McGuire SE, Spratt DE, Souhami L, Roy S, Martin JM, Joseph D, Nabid A, Kishan AU. PMID: 38151191.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    17. In Reply to "Pathogenic/Likely Pathogenic Somatic CDK12 Mutations in Black Men With Prostate Cancer". Oncologist. 2023 Nov 02; 28(11):e1129-e1130. Valle LF, Nickols NG, Yamoah K, Garraway IP, Maxwell KN, Lynch JA. PMID: 37706534; PMCID: PMC10628590.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    18. Long-Term Quality-of-Life Outcomes After Prostate Radiation Therapy With or Without High-Dose-Rate Brachytherapy Boost: Post Hoc Analysis of TROG 03.04 RADAR. Int J Radiat Oncol Biol Phys. 2024 Jul 01; 119(3):813-825. Ong WL, Nikitas J, Joseph D, Steigler A, Millar J, Valle L, Steinberg ML, Ma TM, Reiter RE, Rettig MB, Nickols NG, Chang A, Zaorsky NG, Spratt DE, Romero T, Kishan AU. PMID: 37802226.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    19. Selecting the optimal radiation modality in prostate cancer. Clin Adv Hematol Oncol. 2023 Sep; 21(9):494-501. Valle LF, Kishan AU, Franco A, Ma TM, Nikitas J, Farrell M, Chang AJ, Nickols NG, Steinberg ML. PMID: 37647496.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    20. Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate. J Clin Oncol. 2023 Nov 10; 41(32):5005-5014. Roy S, Romero T, Michalski JM, Feng FY, Efstathiou JA, Lawton CAF, Bolla M, Maingon P, de Reijke T, Joseph D, Ong WL, Sydes MR, Dearnaley DP, Tree AC, Carrier N, Nabid A, Souhami L, Incrocci L, Heemsbergen WD, Pos FJ, Zapatero A, Guerrero A, Alvarez A, San-Segundo CG, Maldonado X, Reiter RE, Rettig MB, Nickols NG, Steinberg ML, Valle LF, Ma TM, Farrell MJ, Neilsen BK, Juarez JE, Deng J, Vangala S, Avril N, Jia AY, Zaorsky NG, Sun Y, Spratt D, Kishan AU, Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium Investigators. PMID: 37639648; PMCID: PMC10642893.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    21. Actionable Genomic Alterations in Prostate Cancer Among Black and White United States Veterans. Oncologist. 2023 06 02; 28(6):e473-e477. Valle LF, Nickols NG, Hausler R, Alba PR, Anglin-Foote T, Perez C, Yamoah K, Rose BS, Kelley MJ, DuVall SL, Garraway IP, Maxwell KN, Lynch JA. PMID: 37084789; PMCID: PMC10243786.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    22. Androgen Drives the Expression of SARS-CoV-2 Entry Proteins in Sinonasal Tissue. J Clin Transl Pathol. 2023; 3(2):49-58. Huang RR, Giafaglione JM, Hashimoto T, Zhang L, Yu W, Rao J, Russo JW, Balk SP, Nickols NG, Rettig MB, Goldstein A, Ye H. PMID: 39363910; PMCID: PMC11449218.
      View in: PubMed   Mentions:
    23. Quantitative assessment of PSMA PET response to therapy in castration-sensitive prostate cancer using an automated imaging platform for disease identification and measurement. Eur J Hybrid Imaging. 2023 Apr 03; 7(1):7. Duriseti S, Berenji G, Tsai S, Rettig M, Nickols NG. PMID: 37009941; PMCID: PMC10068685.
      View in: PubMed   Mentions: 1  
    24. Transcriptomic Heterogeneity in High-risk Prostate Cancer and Implications for Extraprostatic Disease at Presentation on Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol Oncol. 2023 04; 6(2):224-227. Smith CP, Proudfoot JA, Boutros PC, Reiter RE, Valle L, Rettig MB, Nickols NG, Feng FY, Nguyen PL, Nagar H, Spratt DE, Attard G, Weiner A, Weidhaas JB, Calais J, Ma TM, Davicioni E, Xiang M, Kishan AU. PMID: 36870853.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    25. Patterns of Failure in Men With Radiorecurrent Prostate Cancer: A Post Hoc Analysis of 3 Prospective Gallium 68 Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Trials. Int J Radiat Oncol Biol Phys. 2023 08 01; 116(5):1079-1084. Smith CP, Xiang M, Armstrong WR, Nickols NG, Steinberg ML, Reiter RE, Rettig M, Weiner AB, Shen J, Valle L, Czernin J, Calais J, Kishan AU. PMID: 36863416.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    26. Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial. JAMA Oncol. 2023 03 01; 9(3):365-373. Kishan AU, Ma TM, Lamb JM, Casado M, Wilhalme H, Low DA, Sheng K, Sharma S, Nickols NG, Pham J, Yang Y, Gao Y, Neylon J, Basehart V, Cao M, Steinberg ML. PMID: 36633877; PMCID: PMC9857817.
      View in: PubMed   Mentions: 60     Fields:    Translation:Humans
    27. Better Late than Never for Late Toxicity Assessment. Eur Urol. 2023 May; 83(5):391-392. Duriseti S, Berenji GR, Nickols NG, Rettig MB. PMID: 36797143.
      View in: PubMed   Mentions:    Fields:    
    28. Multimodality Therapies for Localized Prostate Cancer. Curr Oncol Rep. 2023 03; 25(3):221-229. Valle LF, Jiang T, Weiner AB, Reiter RE, Rettig MB, Shen J, Chang AJ, Nickols NG, Steinberg ML, Kishan AU. PMID: 36723856; PMCID: PMC11288626.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    29. Mask R-CNN assisted 2.5D object detection pipeline of 68Ga-PSMA-11 PET/CT-positive metastatic pelvic lymph node after radical prostatectomy from solely CT imaging. Sci Rep. 2023 01 30; 13(1):1696. Xu D, Ma M, Cao M, Kishan AU, Nickols NG, Scalzo F, Sheng K. PMID: 36717727; PMCID: PMC9886937.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    30. Early Safety and Efficacy Profile of Homogeneously Dosed Salvage Stereotactic Body Radiotherapy (SBRT) for Intraprostatic Recurrences After Low Dose Rate (LDR) Brachytherapy. Clin Genitourin Cancer. 2023 04; 21(2):208-212. Nikitas J, Cao M, Nickols NG, Valle L, Steinberg ML, Kishan AU. PMID: 36739178.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    31. Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials. J Clin Oncol. 2023 02 01; 41(4):881-892. Ma TM, Sun Y, Malone S, Roach M, Dearnaley D, Pisansky TM, Feng FY, Sandler HM, Efstathiou JA, Syndikus I, Hall EC, Tree AC, Sydes MR, Cruickshank C, Roy S, Bolla M, Maingon P, De Reijke T, Nabid A, Carrier N, Souhami L, Zapatero A, Guerrero A, Alvarez A, Gonzalez San-Segundo C, Maldonado X, Romero T, Steinberg ML, Valle LF, Rettig MB, Nickols NG, Shoag JE, Reiter RE, Zaorsky NG, Jia AY, Garcia JA, Spratt DE, Kishan AU, Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium Investigators. PMID: 36269935; PMCID: PMC9902004.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    32. External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis. Int J Radiat Oncol Biol Phys. 2023 03 01; 115(3):645-653. Patel SA, Ma TM, Wong JK, Stish BJ, Dess RT, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Tran PT, Krauss DJ, Abu-Isa EI, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, DeWeese TL, Tilki D, Ciezki JP, Karnes RJ, Nickols NG, Rettig MB, Feng FY, Berlin A, Tward JD, Davis BJ, Reiter RE, Boutros PC, Romero T, Horwitz EM, Tendulkar RD, Steinberg ML, Spratt DE, Xiang M, Kishan AU. PMID: 36179990.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    33. Quality-of-Life Outcomes and Toxicity Profile Among Patients With Localized Prostate Cancer After Radical Prostatectomy Treated With Stereotactic Body Radiation: The SCIMITAR Multicenter Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2023 01 01; 115(1):142-152. Ma TM, Ballas LK, Wilhalme H, Sachdeva A, Chong N, Sharma S, Yang T, Basehart V, Reiter RE, Saigal C, Chamie K, Litwin MS, Rettig MB, Nickols NG, Yoon SM, Smith L, Gao Y, Steinberg ML, Cao M, Kishan AU. PMID: 36007724; PMCID: PMC11386273.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    34. Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN). Eur Urol. 2022 11; 82(5):487-498. Ma TM, Chu FI, Sandler H, Feng FY, Efstathiou JA, Jones CU, Roach M, Rosenthal SA, Pisansky T, Michalski JM, Bolla M, de Reijke TM, Maingon P, Neven A, Denham J, Steigler A, Joseph D, Nabid A, Souhami L, Carrier N, Incrocci L, Heemsbergen W, Pos FJ, Sydes MR, Dearnaley DP, Tree AC, Syndikus I, Hall E, Cruickshank C, Malone S, Roy S, Sun Y, Zaorsky NG, Nickols NG, Reiter RE, Rettig MB, Steinberg ML, Reddy VK, Xiang M, Romero T, Spratt DE, Kishan AU, Meta-analysis of Randomized trials in Cancer of the Prostate MARCAP Consortium investigators. PMID: 35934601.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    35. High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium. Eur Urol. 2022 07; 82(1):106-114. Kishan AU, Wang X, Sun Y, Romero T, Michalski JM, Ma TM, Feng FY, Sandler HM, Bolla M, Maingon P, De Reijke T, Neven A, Steigler A, Denham JW, Joseph D, Nabid A, Carrier N, Souhami L, Sydes MR, Dearnaley DP, Syndikus I, Tree AC, Incrocci L, Heemsbergen WD, Pos FJ, Zapatero A, Efstathiou JA, Guerrero A, Alvarez A, San-Segundo CG, Maldonado X, Xiang M, Rettig MB, Reiter RE, Zaorsky NG, Ong WL, Dess RT, Steinberg ML, Nickols NG, Roy S, Garcia JA, Spratt DE, MARCAP Consortium. PMID: 35469702.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    36. Effect of Androgen Suppression on Clinical Outcomes in Hospitalized Men With COVID-19: The HITCH Randomized Clinical Trial. JAMA Netw Open. 2022 04 01; 5(4):e227852. Nickols NG, Mi Z, DeMatt E, Biswas K, Clise CE, Huggins JT, Maraka S, Ambrogini E, Mirsaeidi MS, Levin ER, Becker DJ, Makarov DV, Adorno Febles V, Belligund PM, Al-Ajam M, Muthiah MP, Montgomery RB, Robinson KW, Wong YN, Bedimo RJ, Villareal RC, Aguayo SM, Schoen MW, Goetz MB, Graber CJ, Bhattacharya D, Soo Hoo G, Orshansky G, Norman LE, Tran S, Ghayouri L, Tsai S, Geelhoed M, Rettig MB. PMID: 35438754; PMCID: PMC9020208.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    37. Prostate-Centric Versus Bony-Centric Registration in the Definitive Treatment of Node-Positive Prostate Cancer with Simultaneous Integrated Boost: A Dosimetric Comparison. Adv Radiat Oncol. 2022 Jul-Aug; 7(4):100944. Wu TC, Xiang M, Nickols NG, Tenn S, Agazaryan N, Hegde JV, Steinberg ML, Cao M, Kishan AU. PMID: 35521072; PMCID: PMC9061255.
      View in: PubMed   Mentions:
    38. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts. JAMA Oncol. 2022 Mar 01; 8(3):e216871. Kishan AU, Steigler A, Denham JW, Zapatero A, Guerrero A, Joseph D, Maldonado X, Wong JK, Stish BJ, Dess RT, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Tilki D, Karnes RJ, Tosoian JJ, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Jiang T, Ma TM, Xiang M, Philipson R, Chang A, Kupelian PA, Rettig MB, Feng FY, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Boutros PC, Horwitz EM, Tendulkar RD, Spratt DE, Romero T. PMID: 35050303; PMCID: PMC8778608.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    39. Significant changes in macrophage and CD8 T cell densities in primary prostate tumors 2 weeks after SBRT. Prostate Cancer Prostatic Dis. 2023 03; 26(1):207-209. Kane N, Romero T, Diaz-Perez S, Rettig MB, Steinberg ML, Kishan AU, Schaue D, Reiter RE, Knudsen BS, Nickols NG. PMID: 35058580; PMCID: PMC10023555.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    40. Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. Lancet Oncol. 2022 02; 23(2):304-316. Kishan AU, Sun Y, Hartman H, Pisansky TM, Bolla M, Neven A, Steigler A, Denham JW, Feng FY, Zapatero A, Armstrong JG, Nabid A, Carrier N, Souhami L, Dunne MT, Efstathiou JA, Sandler HM, Guerrero A, Joseph D, Maingon P, de Reijke TM, Maldonado X, Ma TM, Romero T, Wang X, Rettig MB, Reiter RE, Zaorsky NG, Steinberg ML, Nickols NG, Jia AY, Garcia JA, Spratt DE, MARCAP Consortium group. PMID: 35051385.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    41. Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care System. JAMA Netw Open. 2022 01 04; 5(1):e2144027. Yamoah K, Lee KM, Awasthi S, Alba PR, Perez C, Anglin-Foote TR, Robison B, Gao A, DuVall SL, Katsoulakis E, Wong YN, Markt SC, Rose BS, Burri R, Wang C, Aboiralor O, Fink AK, Nickols NG, Lynch JA, Garraway IP. PMID: 35040965; PMCID: PMC8767437.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    42. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. JAMA Netw Open. 2021 12 01; 4(12):e2138550. Xiang M, Ma TM, Savjani R, Pollom EL, Karnes RJ, Grogan T, Wong JK, Motterle G, Tosoian JJ, Trock BJ, Klein EA, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Levin-Epstein R, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Huland H, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Alam R, Schwen Z, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Chong N, Kupelian PA, Rettig MB, Zaorsky NG, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Tilki D, Czernin J, Gafita A, Romero T, Calais J, Kishan AU. PMID: 34902034; PMCID: PMC8669522.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    43. Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men: A Meta-analysis. JAMA Netw Open. 2021 12 01; 4(12):e2139769. Ma TM, Romero T, Nickols NG, Rettig MB, Garraway IP, Roach M, Michalski JM, Pisansky TM, Lee WR, Jones CU, Rosenthal SA, Wang C, Hartman H, Nguyen PL, Feng FY, Boutros PC, Saigal C, Chamie K, Jackson WC, Morgan TM, Mehra R, Salami SS, Vince R, Schaeffer EM, Mahal BA, Dess RT, Steinberg ML, Elashoff D, Sandler HM, Spratt DE, Kishan AU. PMID: 34964855; PMCID: PMC8717118.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    44. Refining the definition of biochemical failure in the era of stereotactic body radiation therapy for prostate cancer: The Phoenix definition and beyond. Radiother Oncol. 2022 01; 166:1-7. Ma TM, Roy S, Wu X, Mantz C, Fuller D, Miszczyk L, Napieralska A, Namysl-Kaletka A, Bagshaw HP, Buyyounouski MK, Glicksman R, Loblaw DA, Katz A, Upadhyaya SK, Nickols N, Steinberg ML, Philipson R, Aghdam N, Suy S, Pepin A, Collins SP, Boutros P, Rettig MB, Calais J, Wang M, Zaorsky N, Kishan AU. PMID: 34774650.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    45. Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [18F]DCFPyL (PSMA) imaging for standardized reporting. Eur J Nucl Med Mol Imaging. 2022 02; 49(3):1041-1051. Johnsson K, Brynolfsson J, Sahlstedt H, Nickols NG, Rettig M, Probst S, Morris MJ, Bjartell A, Eiber M, Anand A. PMID: 34463809; PMCID: PMC8803714.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    46. Toxicity After Stereotactic Body Radiation Therapy for Prostate Cancer in Patients With Inflammatory Bowel Disease: A Multi-institutional Matched Case-Control Series. Adv Radiat Oncol. 2021 Nov-Dec; 6(6):100759. Juarez JE, Romero T, Mantz CA, Pepin A, Aghdam N, Suy S, Steinberg ML, Levin-Epstein RG, Nickols NG, Kaplan ID, Meier RM, Pham HT, Linson PW, Hong RL, Buyyounouski MK, Bagshaw HP, Fuller DB, Katz AJ, Loblaw A, Collins SP, Kishan AU. PMID: 34585025; PMCID: PMC8453194.
      View in: PubMed   Mentions: 4  
    47. Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trials. Prostate Cancer Prostatic Dis. 2022 03; 25(1):126-128. Jiang T, Markovic D, Patel J, Juarez JE, Ma TM, Shabsovich D, Nickols NG, Reiter RE, Elashoff D, Rettig MB, Zaorsky NG, Spratt DE, Kishan AU. PMID: 34400799; PMCID: PMC9018418.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    48. Hormonal intervention for the treatment of veterans with COVID-19 requiring hospitalization (HITCH): a multicenter, phase 2 randomized controlled trial of best supportive care vs best supportive care plus degarelix: study protocol for a randomized controlled trial. Trials. 2021 Jul 05; 22(1):431. Nickols NG, Goetz MB, Graber CJ, Bhattacharya D, Soo Hoo G, Might M, Goldstein DB, Wang X, Ramoni R, Myrie K, Tran S, Ghayouri L, Tsai S, Geelhoed M, Makarov D, Becker DJ, Tsay JC, Diamond M, George A, Al-Ajam M, Belligund P, Montgomery RB, Mostaghel EA, Sulpizio C, Mi Z, Dematt E, Tadalan J, Norman LE, Briones D, Clise CE, Taylor ZW, Huminik JR, Biswas K, Rettig MB. PMID: 34225789; PMCID: PMC8256647.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCellsCTClinical Trials
    49. Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. JAMA Netw Open. 2021 07 01; 4(7):e2115312. Kishan AU, Karnes RJ, Romero T, Wong JK, Motterle G, Tosoian JJ, Trock BJ, Klein EA, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Levin-Epstein R, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Braccioforte M, Huland H, Tran PT, Martin S, Martínez-Monge R, Krauss DJ, Abu-Isa EI, Alam R, Schwen Z, Chang AJ, Pisansky TM, Choo R, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Chong N, Kupelian PA, D'Amico AV, Rettig MB, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Tilki D. PMID: 34196715; PMCID: PMC8251338.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    50. aPROMISE: A Novel Automated PROMISE Platform to Standardize Evaluation of Tumor Burden in 18F-DCFPyL Images of Veterans with Prostate Cancer. J Nucl Med. 2022 02; 63(2):233-239. Nickols N, Anand A, Johnsson K, Brynolfsson J, Borreli P, Parikh N, Juarez J, Jafari L, Eiber M, Rettig M. PMID: 34049980.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    51. Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial. BMC Cancer. 2021 May 11; 21(1):538. Ma TM, Lamb JM, Casado M, Wang X, Basehart TV, Yang Y, Low D, Sheng K, Agazaryan N, Nickols NG, Cao M, Steinberg ML, Kishan AU. PMID: 33975579; PMCID: PMC8114498.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    52. Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. Eur Urol. 2021 08; 80(2):142-146. Philipson RG, Romero T, Wong JK, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Braccioforte M, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Valle L, Chong N, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Tilki D, Karnes RJ, Klein EA, Tosoian JJ, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Kupelian PA, Rettig MB, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Kishan AU. PMID: 33985797; PMCID: PMC10262978.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    53. Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol. BMC Cancer. 2021 May 07; 21(1):512. Calais J, Zhu S, Hirmas N, Eiber M, Hadaschik B, Stuschke M, Herrmann K, Czernin J, Kishan AU, Nickols NG, Elashoff D, Fendler WP. PMID: 33962579; PMCID: PMC8103642.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    54. Use and Impact of Positron Emission Tomography/Computed Tomography Prior to Salvage Radiation Therapy in Men with Biochemical Recurrence After Radical Prostatectomy: A Scoping Review. Eur Urol Oncol. 2021 06; 4(3):339-355. Valle L, Shabsovich D, de Meerleer G, Maurer T, Murphy DG, Nickols NG, Vapiwala N, Calais J, Kishan AU. PMID: 33637464.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    55. Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging. Eur Urol Oncol. 2022 02; 5(1):100-103. Ma TM, Gafita A, Shabsovich D, Juarez J, Grogan TR, Thin P, Armstrong W, Sonni I, Nguyen K, Lok V, Reiter RE, Rettig MB, Steinberg ML, Kupelian PA, Yang DD, Muralidhar V, Chu C, Feng F, Savjani R, Deng J, Parikh NR, Nickols NG, Elashoff D, Czernin J, Calais J, Kishan AU. PMID: 33602654; PMCID: PMC10262977.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    56. Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients. Int J Radiat Oncol Biol Phys. 2021 Jul 01; 110(3):731-737. van Dams R, Jiang NY, Fuller DB, Loblaw A, Jiang T, Katz AJ, Collins SP, Aghdam N, Suy S, Stephans KL, Yuan Y, Nickols NG, Murthy V, Telkhade TP, Kupelian PA, Steinberg ML, Romero T, Kishan AU. PMID: 33493615; PMCID: PMC8956505.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    57. Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical Outcome. Eur Urol Focus. 2021 03; 7(2):238-240. Calais J, Armstrong WR, Kishan AU, Booker KM, Hope TA, Fendler WP, Elashoff D, Nickols NG, Czernin J. PMID: 33386288; PMCID: PMC8057677.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    58. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). Eur Urol. 2021 09; 80(3):280-292. Valle LF, Lehrer EJ, Markovic D, Elashoff D, Levin-Epstein R, Karnes RJ, Reiter RE, Rettig M, Calais J, Nickols NG, Dess RT, Spratt DE, Steinberg ML, Nguyen PL, Davis BJ, Zaorsky NG, Kishan AU. PMID: 33309278; PMCID: PMC10262981.
      View in: PubMed   Mentions: 80     Fields:    Translation:Humans
    59. High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors. Clin Cancer Res. 2021 03 01; 27(5):1505-1515. Lin L, Kane N, Kobayashi N, Kono EA, Yamashiro JM, Nickols NG, Reiter RE. PMID: 33219015.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCells
    60. Prostate-specific Membrane Antigen Positron Emission Tomography-guided Radiotherapy. Eur Urol Focus. 2021 03; 7(2):250-253. Kishan AU, Nickols NG, Spratt DE. PMID: 33046413.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    61. Dose-response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control. Radiother Oncol. 2021 01; 154:207-213. Levin-Epstein RG, Jiang NY, Wang X, Upadhyaya SK, Collins SP, Suy S, Aghdam N, Mantz C, Katz AJ, Miszczyk L, Napieralska A, Namysl-Kaletka A, Prionas N, Bagshaw H, Buyyounouski MK, Cao M, Agazaryan N, Dang A, Yuan Y, Kupelian PA, Zaorsky NG, Spratt DE, Mohamad O, Feng FY, Mahal BA, Boutros PC, Kishan AU, Juarez J, Shabsovich D, Jiang T, Kahlon S, Patel A, Patel J, Nickols NG, Steinberg ML, Fuller DB, Kishan AU. PMID: 33035622; PMCID: PMC7956167.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    62. The Impact of 18F-DCFPyL PET-CT Imaging on Initial Staging, Radiation, and Systemic Therapy Treatment Recommendations for Veterans With Aggressive Prostate Cancer. Adv Radiat Oncol. 2020 Nov-Dec; 5(6):1364-1369. Parikh NR, Tsai S, Bennett C, Lewis M, Sadeghi A, Lorentz W, Cheung M, Garraway I, Aronson W, Kishan AU, Bahri S, Vahidi K, Calais J, Ishimitsu D, Rettig M, Nickols NG, Jafari L. PMID: 33305100; PMCID: PMC7718503.
      View in: PubMed   Mentions: 1  
    63. False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial. Eur J Nucl Med Mol Imaging. 2021 02; 48(2):501-508. Fendler WP, Calais J, Eiber M, Simko JP, Kurhanewicz J, Santos RD, Feng FY, Reiter RE, Rettig MB, Nickols NG, Kishan AU, PSMA PET Reader Group, Slavik R, Carroll PR, Lawhn-Heath C, Herrmann K, Czernin J, Hope TA. PMID: 32808077; PMCID: PMC7835157.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    64. Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients. Radiother Oncol. 2020 10; 151:26-32. Levin-Epstein R, Cook RR, Wong JK, Stock RG, Jeffrey Demanes D, Collins SP, Aghdam N, Suy S, Mantz C, Katz AJ, Nickols NG, Miszczyk L, Napieralska A, Namysl-Kaletka A, Prionas ND, Bagshaw H, Buyyounouski MK, Cao M, Mahal BA, Shabsovich D, Dang A, Yuan Y, Rettig MB, Chang AJ, Jackson WC, Spratt DE, Lehrer EJ, Zaorsky NG, Kupelian PA, Steinberg ML, Horwitz EM, Jiang NY, Kishan AU. PMID: 32663537.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    65. The intraprostatic immune environment after stereotactic body radiotherapy is dominated by myeloid cells. Prostate Cancer Prostatic Dis. 2021 03; 24(1):135-139. Nickols NG, Ganapathy E, Nguyen C, Kane N, Lin L, Diaz-Perez S, Nazarian R, Mathis C, Felix C, Basehart V, Zomorodian N, Kwak J, Kishan AU, King CR, Kupelian PA, Rettig MB, Steinberg ML, Cao M, Knudsen BS, Chu FI, Romero T, Elashoff D, Reiter RE, Schaue D. PMID: 32647353; PMCID: PMC7794088.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCellsCTClinical Trials
    66. Phase 1 Trial of Stereotactic Body Radiation Therapy Neoadjuvant to Radical Prostatectomy for Patients With High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2020 11 15; 108(4):930-935. Parikh NR, Kishan AU, Kane N, Diaz-Perez S, Ganapathy E, Nazarian R, Felix C, Mathis C, Bradley M, Sachdeva A, Wyatt B, Basehart V, Zomorodian N, Lin L, King CR, Kupelian PA, Rettig MB, Steinberg ML, Cao M, Knudsen BS, Elashoff D, Schaue D, Reiter RE, Nickols NG. PMID: 32562839; PMCID: PMC8261839.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    67. Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer. Int J Radiat Oncol Biol Phys. 2020 11 15; 108(4):917-926. Parikh NR, Chang EM, Nickols NG, Rettig MB, Raldow AC, Steinberg ML, Koontz BF, Vapiwala N, Deville C, Feng FY, Spratt DE, Reiter RE, Phillips R, Ost P, Tran PT, Kishan AU. PMID: 32544574; PMCID: PMC11386274.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    68. Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. Eur Urol. 2020 09; 78(3):327-332. Kishan AU, Romero T, Alshalalfa M, Liu Y, Tran PT, Nickols NG, Ye H, Sajed D, Rettig MB, Reiter RE, Garraway IP, Spratt DE, Freedland SJ, Zhao X, Li Z, Deek M, Livingstone J, Mahal BA, Nguyen PL, Feng FY, Den RB, Schaeffer EM, Lotan TL, Karnes RJ, Klein EA, Ross AE, Grogan T, Davicioni E, Elashoff D, Boutros PC, Weidhaas JB. PMID: 32461072; PMCID: PMC8954568.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    69. Development and Validation of a Comprehensive Multivariate Dosimetric Model for Predicting Late Genitourinary Toxicity Following Prostate Cancer Stereotactic Body Radiotherapy. Front Oncol. 2020; 10:786. Valle LF, Ruan D, Dang A, Levin-Epstein RG, Patel AP, Weidhaas JB, Nickols NG, Lee PP, Low DA, Qi XS, King CR, Steinberg ML, Kupelian PA, Cao M, Kishan AU. PMID: 32509582; PMCID: PMC7251156.
      View in: PubMed   Mentions: 1  
    70. Clinical Assessment of Prostate Displacement and Planning Target Volume Margins for Stereotactic Body Radiotherapy of Prostate Cancer. Front Oncol. 2020; 10:539. Levin-Epstein R, Qiao-Guan G, Juarez JE, Shen Z, Steinberg ML, Ruan D, Valle L, Nickols NG, Kupelian PA, King CR, Cao M, Kishan AU. PMID: 32373529; PMCID: PMC7177009.
      View in: PubMed   Mentions: 19  
    71. Impact of 68Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study. J Nucl Med. 2020 08; 61(8):1153-1160. Sonni I, Eiber M, Fendler WP, Alano RM, Vangala SS, Kishan AU, Nickols N, Rettig MB, Reiter RE, Czernin J, Calais J. PMID: 31924715; PMCID: PMC7413232.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCTClinical Trials
    72. Optimal patient selection for stereotactic body radiotherapy. Lancet Oncol. 2019 12; 20(12):e661. Kishan AU, Collins SP, Nickols NG. PMID: 31797787.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    73. Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials. Eur Urol. 2020 02; 77(2):201-208. Kishan AU, Chu FI, King CR, Seiferheld W, Spratt DE, Tran P, Wang X, Pugh SE, Sandler KA, Bolla M, Maingon P, De Reijke T, Nickols NG, Rettig M, Drakaki A, Liu ST, Reiter RE, Chang AJ, Feng FY, Sajed D, Nguyen PL, Kupelian PA, Steinberg ML, Boutros PC, Elashoff D, Collette L, Sandler HM. PMID: 31718822; PMCID: PMC7008470.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    74. Gantry-Mounted Linear Accelerator-Based Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer. Adv Radiat Oncol. 2020 May-Jun; 5(3):404-411. Dang AT, Levin-Epstein RG, Shabsovich D, Cao M, King C, Chu FI, Mantz CA, Stephans KL, Reddy CA, Loblaw DA, Cheung P, Scorsetti M, Cozzi L, DeNittis AS, Wang Y, Zaorsky N, Nickols NG, Kupelian PA, Steinberg ML, Kishan AU. PMID: 32529134; PMCID: PMC7276661.
      View in: PubMed   Mentions: 2  
    75. Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics After Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2019 11 01; 105(3):628-636. Jiang NY, Dang AT, Yuan Y, Chu FI, Shabsovich D, King CR, Collins SP, Aghdam N, Suy S, Mantz CA, Miszczyk L, Napieralska A, Namysl-Kaletka A, Bagshaw H, Prionas N, Buyyounouski MK, Jackson WC, Spratt DE, Nickols NG, Steinberg ML, Kupelian PA, Kishan AU. PMID: 31276777.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    76. Testosterone Levels and Sexual Quality of Life After Stereotactic Body Radiation Therapy for Prostate Cancer: A Multi-Institutional Analysis of Prospective Trials. Int J Radiat Oncol Biol Phys. 2019 09 01; 105(1):149-154. Yuan Y, Aghdam N, King CR, Fuller DB, Weng J, Chu FI, Mardirossian G, Patel A, Nickols NG, Kupelian PA, Steinberg ML, Collins SP, Kishan AU. PMID: 31108142.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    77. Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis. Eur Urol. 2020 01; 77(1):3-10. Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU. PMID: 30992160; PMCID: PMC7521828.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    78. Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease. BMC Cancer. 2019 Apr 01; 19(1):291. Parikh NR, Huiza C, Patel JS, Tsai S, Kalpage N, Thein M, Pitcher S, Lee SP, Inouye WS, Jordan ML, Sanati H, Jafari L, Bennett CJ, Gin GE, Kishan AU, Reiter RE, Lewis M, Sadeghi A, Aronson WJ, Garraway IP, Rettig MB, Nickols NG. PMID: 30935383; PMCID: PMC6444674.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    79. MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. Prostate Cancer Prostatic Dis. 2019 12; 22(4):531-538. Nickols NG, Nazarian R, Zhao SG, Tan V, Uzunangelov V, Xia Z, Baertsch R, Neeman E, Gao AC, Thomas GV, Howard L, De Hoedt AM, Stuart J, Goldstein T, Chi K, Gleave ME, Graff JN, Beer TM, Drake JM, Evans CP, Aggarwal R, Foye A, Feng FY, Small EJ, Aronson WJ, Freedland SJ, Witte ON, Huang J, Alumkal JJ, Reiter RE, Rettig MB. PMID: 30804427; PMCID: PMC6853839.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCells
    80. Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer. Eur Urol Oncol. 2021 04; 4(2):327-330. Wang C, Raldow AC, Nickols NG, Nguyen PL, Spratt DE, Dess RT, Yu JB, King CR, Chu FI, Chamie K, Litwin MS, Saigal CS, Reiter RE, Liu ST, Rettig MB, Chang AJ, Steinberg ML, Kupelian PA, Kishan AU. PMID: 31411981.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    81. Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer. JAMA Netw Open. 2019 02 01; 2(2):e188006. Kishan AU, Dang A, Katz AJ, Mantz CA, Collins SP, Aghdam N, Chu FI, Kaplan ID, Appelbaum L, Fuller DB, Meier RM, Loblaw DA, Cheung P, Pham HT, Shaverdian N, Jiang N, Yuan Y, Bagshaw H, Prionas N, Buyyounouski MK, Spratt DE, Linson PW, Hong RL, Nickols NG, Steinberg ML, Kupelian PA, King CR. PMID: 30735235; PMCID: PMC6484596.
      View in: PubMed   Mentions: 126     Fields:    Translation:Humans
    82. Correction to: Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]. BMC Cancer. 2019 01 21; 19(1):97. Calais J, Czernin J, Fendler WP, Elashoff D, Nickols NG. PMID: 30665383; PMCID: PMC6341574.
      View in: PubMed   Mentions: 1     Fields:    
    83. Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]. BMC Cancer. 2019 Jan 07; 19(1):18. Calais J, Czernin J, Fendler WP, Elashoff D, Nickols NG. PMID: 30616601; PMCID: PMC6322287.
      View in: PubMed   Mentions: 40     Fields:    
    84. Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis. JAMA Oncol. 2019 01 01; 5(1):91-96. Kishan AU, Wang X, Seiferheld W, Collette L, Sandler KA, Sandler HM, Bolla M, Maingon P, De Reijke T, Hanks GE, Nickols NG, Rettig M, Drakaki A, Reiter RE, Spratt DE, Kupelian PA, Steinberg ML, King CR. PMID: 30326032; PMCID: PMC6440243.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    85. Spatial Mapping of Myeloid Cells and Macrophages by Multiplexed Tissue Staining. Front Immunol. 2018; 9:2925. Saylor J, Ma Z, Goodridge HS, Huang F, Cress AE, Pandol SJ, Shiao SL, Vidal AC, Wu L, Nickols NG, Gertych A, Knudsen BS. PMID: 30619287; PMCID: PMC6302234.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    86. Treatment of the primary tumor in metastatic prostate cancer. World J Urol. 2019 Dec; 37(12):2597-2606. Yuan Y, Kishan AU, Nickols NG. PMID: 30456709.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    87. Interference with DNA repair after ionizing radiation by a pyrrole-imidazole polyamide. PLoS One. 2018; 13(5):e0196803. Diaz-Perez S, Kane N, Kurmis AA, Yang F, Kummer NT, Dervan PB, Nickols NG. PMID: 29715291; PMCID: PMC5929528.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    88. Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer. J Nucl Med. 2018 11; 59(11):1714-1721. Calais J, Kishan AU, Cao M, Fendler WP, Eiber M, Herrmann K, Ceci F, Reiter RE, Rettig MB, Hegde JV, Shaverdian N, King CR, Steinberg ML, Czernin J, Nickols NG. PMID: 29653978; PMCID: PMC6225538.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCTClinical Trials
    89. Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study. Int J Radiat Oncol Biol Phys. 2018 07 15; 101(4):883-888. Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU. PMID: 29976500.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    90. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. JAMA. 2018 03 06; 319(9):896-905. Kishan AU, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Sandler KA, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Stephenson AJ, Klein EA, Song DY, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco S, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR. PMID: 29509865; PMCID: PMC5885899.
      View in: PubMed   Mentions: 114     Fields:    Translation:Humans
    91. The Utility of PET/CT in the Planning of External Radiation Therapy for Prostate Cancer. J Nucl Med. 2018 04; 59(4):557-567. Calais J, Cao M, Nickols NG. PMID: 29301928; PMCID: PMC6910632.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    92. Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. J Nucl Med. 2018 03; 59(3):434-441. Calais J, Fendler WP, Eiber M, Gartmann J, Chu FI, Nickols NG, Reiter RE, Rettig MB, Marks LS, Ahlering TE, Huynh LM, Slavik R, Gupta P, Quon A, Allen-Auerbach MS, Czernin J, Herrmann K. PMID: 29242398; PMCID: PMC5868499.
      View in: PubMed   Mentions: 64     Fields:    Translation:Humans
    93. 68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning. J Nucl Med. 2018 02; 59(2):230-237. Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, Sandler K, Chu FI, King CR, Steinberg ML, Rauscher I, Schmidt-Hegemann NS, Poeppel T, Hetkamp P, Ceci F, Herrmann K, Fendler WP, Eiber M, Nickols NG. PMID: 29123013; PMCID: PMC5807533.
      View in: PubMed   Mentions: 97     Fields:    Translation:Humans
    94. Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy. Brachytherapy. 2017 Nov - Dec; 16(6):1106-1112. Hegde JV, Demanes DJ, Veruttipong D, Raince J, Park SJ, Raman SS, Nickols NG, King CR, Kishan AU, Steinberg ML, Kamrava M. PMID: 28807747.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    95. A Pyrrole-Imidazole Polyamide Is Active against Enzalutamide-Resistant Prostate Cancer. Cancer Res. 2017 05 01; 77(9):2207-2212. Kurmis AA, Yang F, Welch TR, Nickols NG, Dervan PB. PMID: 28360139; PMCID: PMC5480898.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    96. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. Eur Urol. 2017 05; 71(5):766-773. Kishan AU, Shaikh T, Wang PC, Reiter RE, Said J, Raghavan G, Nickols NG, Aronson WJ, Sadeghi A, Kamrava M, Demanes DJ, Steinberg ML, Horwitz EM, Kupelian PA, King CR. PMID: 27452951; PMCID: PMC10262972.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    97. SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer. Pract Radiat Oncol. 2016 Jul-Aug; 6(4):268-275. Kishan AU, Wang PC, Upadhyaya SK, Hauswald H, Demanes DJ, Nickols NG, Kamrava M, Sadeghi A, Kupelian PA, Steinberg ML, Prionas ND, Buyyounouski MK, King CR. PMID: 26850649.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    98. Size-selective collection of circulating tumor cells using Vortex technology. Lab Chip. 2014 Jan 07; 14(1):63-77. Sollier E, Go DE, Che J, Gossett DR, O'Byrne S, Weaver WM, Kummer N, Rettig M, Goldman J, Nickols N, McCloskey S, Kulkarni RP, Di Carlo D. PMID: 24061411.
      View in: PubMed   Mentions: 176     Fields:    Translation:HumansCells
    99. Animal toxicity of hairpin pyrrole-imidazole polyamides varies with the turn unit. J Med Chem. 2013 Sep 26; 56(18):7449-57. Yang F, Nickols NG, Li BC, Szablowski JO, Hamilton SR, Meier JL, Wang CM, Dervan PB. PMID: 24015881; PMCID: PMC3788622.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    100. Activity of a Py-Im polyamide targeted to the estrogen response element. Mol Cancer Ther. 2013 May; 12(5):675-84. Nickols NG, Szablowski JO, Hargrove AE, Li BC, Raskatov JA, Dervan PB. PMID: 23443804; PMCID: PMC3651785.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    101. Antitumor activity of a pyrrole-imidazole polyamide. Proc Natl Acad Sci U S A. 2013 Jan 29; 110(5):1863-8. Yang F, Nickols NG, Li BC, Marinov GK, Said JW, Dervan PB. PMID: 23319609; PMCID: PMC3562772.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansAnimalsCells
    102. Gene expression changes in a tumor xenograft by a pyrrole-imidazole polyamide. Proc Natl Acad Sci U S A. 2012 Oct 02; 109(40):16041-5. Raskatov JA, Nickols NG, Hargrove AE, Marinov GK, Wold B, Dervan PB. PMID: 22988074; PMCID: PMC3479560.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    103. Single-dose pharmacokinetic and toxicity analysis of pyrrole-imidazole polyamides in mice. Cancer Chemother Pharmacol. 2012 Oct; 70(4):617-25. Synold TW, Xi B, Wu J, Yen Y, Li BC, Yang F, Phillips JW, Nickols NG, Dervan PB. PMID: 22907527; PMCID: PMC3456924.
      View in: PubMed   Mentions: 16     Fields:    Translation:Animals
    104. Repression of DNA-binding dependent glucocorticoid receptor-mediated gene expression. Proc Natl Acad Sci U S A. 2009 Sep 29; 106(39):16598-603. Muzikar KA, Nickols NG, Dervan PB. PMID: 19805343; PMCID: PMC2744631.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCells
    105. Modulating hypoxia-inducible transcription by disrupting the HIF-1-DNA interface. ACS Chem Biol. 2007 Aug 17; 2(8):561-71. Nickols NG, Jacobs CS, Farkas ME, Dervan PB. PMID: 17708671; PMCID: PMC3060759.
      View in: PubMed   Mentions: 64     Fields:    Translation:Cells
    106. Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide. Proc Natl Acad Sci U S A. 2007 Jun 19; 104(25):10418-23. Nickols NG, Dervan PB. PMID: 17566103; PMCID: PMC1965528.
      View in: PubMed   Mentions: 94     Fields:    Translation:HumansCells
    107. Improved nuclear localization of DNA-binding polyamides. Nucleic Acids Res. 2007; 35(2):363-70. Nickols NG, Jacobs CS, Farkas ME, Dervan PB. PMID: 17175539; PMCID: PMC1802595.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCells
    108. Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proc Natl Acad Sci U S A. 2004 Nov 30; 101(48):16768-73. Olenyuk BZ, Zhang GJ, Klco JM, Nickols NG, Kaelin WG, Dervan PB. PMID: 15556999; PMCID: PMC534742.
      View in: PubMed   Mentions: 88     Fields:    Translation:HumansCells
    109. Influence of structural variation on nuclear localization of DNA-binding polyamide-fluorophore conjugates. Nucleic Acids Res. 2004; 32(9):2802-18. Edelson BS, Best TP, Olenyuk B, Nickols NG, Doss RM, Foister S, Heckel A, Dervan PB. PMID: 15155849; PMCID: PMC419610.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansAnimalsCells
    110. Nuclear localization of pyrrole-imidazole polyamide-fluorescein conjugates in cell culture. Proc Natl Acad Sci U S A. 2003 Oct 14; 100(21):12063-8. Best TP, Edelson BS, Nickols NG, Dervan PB. PMID: 14519850; PMCID: PMC218713.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansAnimalsCells
    Nicholas's Networks
    Concepts (281)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (80)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California